Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–63 of 63 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo for Adalimumab Clear all

Conditions: Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Interventions: Adalimumab Injection [Humira], Saline Solution for Injection; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 5 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Torrance, California

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Placebo, Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Beverly Hills, California • Encino, California • Irvine, California + 6 more

Conditions: Psoriasis
Interventions: Placebo, Adalimumab; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more

Conditions: Interstitial Cystitis
Interventions: Adalimumab, inactive drug; Drug · Other
Lead sponsor: ICStudy, LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Escondido, California

Conditions: Arthritis, Rheumatoid
Interventions: Adalimumab, CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 22
States / cities: Mesa, Arizona • Little Rock, Arkansas • Northridge, California + 17 more

Conditions: REM Sleep Behavior Disorder
Interventions: Adalimumab, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Los Angeles, California • Aurora, Colorado • North Haven, Connecticut + 14 more

Conditions: Psoriasis, Arthritic
Interventions: Ixekizumab, Placebo, Adalimumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 34 more

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 48
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib and placebo injections, Adalimumab and placebo of fostamatinib, Placebo of fostamatinib, fostamatinib, and placebo injections; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 40
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 37 more

Conditions: Spondylitis, Ankylosing
Interventions: Ixekizumab, Placebo, Adalimumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 34
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more

Conditions: Rheumatoid Arthritis
Interventions: Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w; Drug
Lead sponsor: R-Pharm International, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 64
States / cities: Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more

Conditions: Rheumatoid Arthritis
Interventions: adalimumab, methotrexate, placebo; Biological · Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 1,032 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 49
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more

Conditions: Benign Prostatic Hyperplasia (BPH)
Interventions: Adalimumab; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Rheumatoid Arthritis
Interventions: BMS-945429 Placebo, BMS-945429, Methotrexate, Methotrexate Placebo, Adalimumab Placebo, Adalimumab; Drug · Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 13
States / cities: Peoria, Arizona • San Diego, California • Trumbull, Connecticut + 10 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: ABBV-3373, Placebo for ABBV-3373, Adalimumab, Placebo for adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 18
States / cities: Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 15 more

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

Efficacy Study of Adalimumab to Treat Interstitial Cystitis

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

Effects of TNF Blockade on Human BPH/LUTS

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)